<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF"><gtr:id>C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF</gtr:id><gtr:name>University of Paris 6</gtr:name><gtr:address><gtr:line1>Bat 121</gtr:line1><gtr:line4>Paris</gtr:line4><gtr:postCode>F-75252</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5007777D-75C9-4C55-9B58-E275FB2ED626"><gtr:id>5007777D-75C9-4C55-9B58-E275FB2ED626</gtr:id><gtr:name>Department of Pharmacology and Clinical Neuroscience</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Cardiovascular</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A"><gtr:id>9DB89E2F-30C0-4BB4-8F71-C9E1288FE25A</gtr:id><gtr:name>Guy's and St Thomas' NHS Foundation Trust</gtr:name><gtr:address><gtr:line1>Westminster Bridge Road</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SE1 7EH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/99A20F70-F6B7-43DE-94E4-7004FAE6291E"><gtr:id>99A20F70-F6B7-43DE-94E4-7004FAE6291E</gtr:id><gtr:name>Ludwig Maximilians University Munich</gtr:name><gtr:address><gtr:line1>Geschwister-Scholl-Platz 1</gtr:line1><gtr:postCode>D-80539</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF"><gtr:id>C96DB0B8-CEAC-4B25-B19B-81F9AF857DFF</gtr:id><gtr:name>University of Paris 6</gtr:name><gtr:address><gtr:line1>Bat 121</gtr:line1><gtr:line4>Paris</gtr:line4><gtr:postCode>F-75252</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5007777D-75C9-4C55-9B58-E275FB2ED626"><gtr:id>5007777D-75C9-4C55-9B58-E275FB2ED626</gtr:id><gtr:name>Department of Pharmacology and Clinical Neuroscience</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BAA31689-3C17-4D79-8A8C-FCC900A3CD99"><gtr:id>BAA31689-3C17-4D79-8A8C-FCC900A3CD99</gtr:id><gtr:firstName>Mathias</gtr:firstName><gtr:surname>Gautel</gtr:surname><gtr:orcidId>0000-0003-4027-9803</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ010456%2F1"><gtr:id>9D12FF7C-6714-4DD8-BA4A-6EC5768B9095</gtr:id><gtr:title>Sarcomeric signalling by giant muscle M-band proteins in health and disease</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J010456/1</gtr:grantReference><gtr:abstractText>The function of striated muscles, so called because of their highly regular striation pattern when viewed in a microscope, is crucial for the movement of our body and heart muscles. These stripes are formed from the repetitive arrangements of molecular machines, called sarcomeres that generate force and movement. In the sarcomere, three systems of molecular filaments are working together: actin filaments, which are held together at the Z-disk, myosin filaments, held together at the M-band, and the giant protein filament titin, which links the actin and myosin filaments. Muscle responds rapidly to changes in use, with disuse leading to muscle loss (called atrophy) and exercise leading to muscle growth (called hypertrophy). These processes need to be constantly balanced, and are linked in a coordinated way to those controlling muscle repair by making new proteins for sarcomere repair and replacement of other unwanted or damaged components of the cell. Signals controlling muscle growth, atrophy and repair signals are emerging to originate at the M-band and the Z-disk. These structures contain proteins that can sense mechanical stress, the most important factor controlling muscle growth and atrophy (as seen by the rapid loss of more than half the muscle mass in two weeks when muscles are immobilised in a plaster cast). Many of these proteins, however, remain enigmatic or haven't even been discovered, and often even their most fundamental functions have not been elucidated. Yet, when the integration of the M-band as a machinery combining structural, mechanical and communication functions is disrupted by genetic defects or extreme muscle inactivity (for instance in intensive care unit patients), severe muscle diseases are the result. This study will shed light on the compositions and regulation of the M-band, its role as a sensor for mechanical stress, and why mutations in two of the giant proteins that are involved in its assembly, titin and obscurin, can lead to muscle disease.</gtr:abstractText><gtr:technicalSummary>This project will use a cross-disciplinary approach using to understand the links of the sarcomeric M-band to protein kinase signalling pathways controlling the turnover of myofibrils, and how mutations in the major sarcomeric protein titin affect this interplay of cellular structure, mechanics and signalling. It will use animal models to inform us on basic biological parameters of titin kinase as well as to allow us studying models of human disease. Cardiomyocyte cultures from neonatal and adult rodents will be used as easily manipulated models for studying cellular responses to mechanical stimuli, as well as for their particular suitability for live imaging approaches, which will inform us on the temporal dynamics and interactions of the M-band components studied, and the impact of defined mutations thereon. This will be complemented by super-resolution confocal microscopy and advanced image analysis (stress maps) to visualize with resolution approaching the dimension of individual M-band components the spatial relations of these, and the changes induced by mechanical activity or genetic disruptions in anmal models or patient biopsies. An underpinning activity will be the protein biochemistry necessary to generate the enzymes and structural proteins required for functional and kinetic studies, and for the nanoscale force measurements by single-molecule force spectroscopy and optical tweezers. Similarly, the structural analysis by X-ray crystallography, small-angle X-ray scattering and electron microscopy with single-particle reconstruction will be highly dependent on our proven ability to generate highly functional proteins for these types of studies, which will not only show basic molecular principles of M-band protein interactions or enzyme structure, but reveal the mechanisms of pathogenic mutations and guide the development of small molecule compounds that could target such interaction interfaces or active sites.</gtr:technicalSummary><gtr:potentialImpactText>Our research addresses both fundamental questions of striated muscle biology- the assembly of sarcomeric structures, the identification of novel components thereof, and the mechanisms governing their controlled turnover- as well as the pathomechanisms of hereditary and acquired muscle disease. Research from our laboratory has been, and will be, of benefit for the diagnosis and treatment of acquired and hereditary myopathies.

Our research will foster economic performance by benefiting commercial private companies interested in new physiological targets for muscle diseases. Currently, we are aware that output from our research on titin kinase has already spawned a new drug-discovery programme by a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of muscle disorders (Rigel Pharmaceuticals, San Francisco, USA; www.rigel.com). Rigel collaborates with e.g. AstraZeneca, Pfizer, Merck, Johnson &amp;amp; Johnson and Novartis in these activities. We expect that new pathways and deeper insight into known pathways emerging during our proposed programme will benefit development-oriented companies like Rigel in implementing new drug development programmes, and we remain in active communication to achieve and facilitate this. For example, we make reagents and protocols available for testing biological activities of M-band signalling proteins that can be implemented in high-throughput screens. 
We also propose here to generate new monoclonal antibodies against M-band titin that will be of considerable value in the diagnostic of M-band myopathies, where deletion of parts of the titin C-terminus emerges as a common feature and an unmet need for standardised reagents in diagnostic application arises. We will collaborate with UK partners in the generation and eventual commercialisation of these reagents. These impacts can be realised within the tenure of the grant or shortly afterwards.

Patients and patient support groups.
We predict that the proposed research will be of benefit to patients and patient support organizations (e.g. international and national muscular dystrophy, and heart associations), by raising awareness of titin mutations as causes of hereditary muscle diseases, and their diagnostic and prognostic implications. These impacts can be realised within the tenure of the grant or shortly afterwards.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2124556</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Biophysics</gtr:department><gtr:description>Biophysics of cytoskeletal proteins</gtr:description><gtr:id>2BD7560F-AD77-494D-A7C5-BC191A5812C0</gtr:id><gtr:impact>One joint paper: Pernigo et al., Proc. Natl. Acad. Sci. USA, (2010). 107(7): p. 2908-2913.
Multi-disciplinary collaboration between the physics team in Munich with expertise in optical trap measurements of protein-protein complexes, and our input in muscle protein biochemistry, analysis of sarcomeric protein interactions, and muscle cell biology.</gtr:impact><gtr:partnerContribution>technical and conceptual advances on single-molecule biophysics</gtr:partnerContribution><gtr:piContribution>Concept of research project, generation of recombinant proteins and cell biological validation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pierre and Marie Curie University - Paris 6</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>UMR 787 (Institute of Myology)</gtr:department><gtr:description>Early-onset Myopathies</gtr:description><gtr:id>344E6987-513E-4056-BEB7-D072F2C6280F</gtr:id><gtr:impact>Two joint publications:
Carmignac et al., Ann. Neurol., (2007). 61(4): p. 340 - 351.
Fukuzawa et al., J. Cell Sci., (2008). 121(11): p. 1841-1851.
A multi-disciplinary, translational collaboration that elucidates the disease mechanisms of novel early-onset myopathies.</gtr:impact><gtr:partnerContribution>Has provided valuable insight into the human biology of titin kinase and M-band titin by identifying crucial regions affected in early-onset myopathies.</gtr:partnerContribution><gtr:piContribution>We analyse sarcomeric protein mutations leading to early-onset (paediatric) myopathies on the biochemical, biophysical and cell-biological level.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guy's and St Thomas' NHS Foundation Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Paediatric Neurology</gtr:department><gtr:description>Congenital autophagy disorders</gtr:description><gtr:id>7C751D5E-6D1B-4EBB-96D8-8C221F09EE76</gtr:id><gtr:impact>myotubular myopathy trust award</gtr:impact><gtr:partnerContribution>Identifies patients and candidate disease genes</gtr:partnerContribution><gtr:piContribution>Analyse the impairment of the autophagy/lysosomal pathway and muscle ubiquitin ligases in hereditary paediatric disorders with myopathy/cardiomyopathy.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Pharmacology and Clinical Neuroscience</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Clinical Neurophysiology Unit</gtr:department><gtr:description>Critical illness myopathy</gtr:description><gtr:id>A928ACA7-3534-42EF-8EE4-6A632C145957</gtr:id><gtr:impact>One joint paper:
Ochala et al., J. Physiol., (2011). 589(8): p. 2007-26.
A multi-disciplinary collaboration that combines clinical expertise in critical illness myopathy in Umea with our expertise in muscle mechanosignalling.</gtr:impact><gtr:partnerContribution>We receive samples from a unique rat model of critical illness myopathy to assess changes in mechanosignalling complexes in the pathogenesis of this condition</gtr:partnerContribution><gtr:piContribution>We analyse muscle samples from a unique rat model for critical illness myopathy developed in Umea for biochemical and cellular changes in sarcomeric mechanosignalling complexes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ludwig Maximilian University of Munich (LMU Munich)</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Mechanoenzymatics</gtr:description><gtr:id>59E78480-C006-476E-A4DA-A11662F50879</gtr:id><gtr:impact>Two 2008 publications (Puchner et al., Proc. Natl. Acad. Sci. USA, (2008). 105(36): p. 13385-13390. Puchner et al., Biophys. J., (2008). 95(1): p. 426-434.), and one recent paper (Stahl et al., Biophys. J., (2011). 101(8): p. 1978-86). Ongoing multi-disciplinary work with the Munich physics team, and our expertise and conceptual background in muscle biochemistry and cell biology.</gtr:impact><gtr:partnerContribution>publications, shared personnel</gtr:partnerContribution><gtr:piContribution>We expanded our research on mechanoenzymatic kinase signalling in collaboration with the Gaub team at the LMU. We identified new target proteins, expressed those and designed new studies.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BHF lab visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7E4103D8-EC7F-4E05-ACC4-6FCF220B0CC1</gtr:id><gtr:impact>Visit of BHF fundraising and outreach teams to DR. Yin-Biao Sun's team. Introduced the Randall Division and presented cardiovascular research activities in cell and molecular biophysics.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BHF donor lab visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>45E20542-45A9-447A-9B78-4146C9804CF4</gtr:id><gtr:impact>12 donors attended this visit, which included lab tours, practical demonstrations and short presentations.

A cheque over &amp;pound;10000 was issued on the spot.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1169309</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Programme Grant</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>RG/15/8/31480</gtr:fundingRef><gtr:id>9AD3DB93-F5E0-4E18-979E-26B0453DD495</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1647764</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>'Next Generation Optical Microscopy' - co-funded by MRC and EPSRC</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K015664/1</gtr:fundingRef><gtr:id>459527C4-362E-431B-9A57-952CF76F8423</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>536256</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Collaborative Award in Sciences</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>201543/Z/16/Z</gtr:fundingRef><gtr:id>A8F2A513-3E95-405C-88AD-9C79A01B90A3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1511811</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHF Professorship-renewal</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:fundingRef>CH/08/001</gtr:fundingRef><gtr:id>CE001827-F59C-4172-B840-FE7323D1B1D1</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>citation in clinical reviews in the neurological area</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>7085722D-D67B-4C9A-BC2B-FEC9E8D6AF71</gtr:id><gtr:impact>improved genetic diagnostics of early-onset myopathies</gtr:impact><gtr:type>Citation in clinical reviews</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Contribution to diagnostic guidelines for titinopathies</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:guidelineTitle>219th ENMC International Workshop Titinopathies International database of titin mutations and phenotypes, Heemskerk, The Netherlands, 29 April-1 May 2016</gtr:guidelineTitle><gtr:id>3DC14F80-E49E-47E3-AB07-35E7F7A6EE5C</gtr:id><gtr:impact>Contributions led to establishment of evidence-based criteria how to define pathogenic TTN mutations, which parameters should be included in a titinopathy database, and which clinical parameters should be preferentially monitored in affected patients for best health outcomes and improved diagnosis.</gtr:impact><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>antibodies against Nbr1, MURF2 for immunohistochemistry and Western blotting</gtr:description><gtr:id>64986896-E50C-4670-A329-6C8DF9837034</gtr:id><gtr:impact>Research Material used for differential diagnosis for Human Myopathy with Early Respiratory Failure</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>reagents and diagnostic criteria for Human Myopathy with Early Respiratory Failure</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>antibodies against titin and obscurin, obscurin-like 1 used in immunohistochemistry and Western blotting of patient material</gtr:description><gtr:id>D2F78903-C36F-4DED-8315-EAE8C5E4DDF8</gtr:id><gtr:impact>Research Material used for differential diagnosis for Human Myopathy with Early Respiratory Failure, Salih Myopathy, tibial muscular dystrophy (TMD) and LGMD2J</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>reagents and diagnostic criteria for Salih Myopathy and LGMD2J</gtr:title><gtr:type>Antibody</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8D05D9D6-BFC5-46B7-B0CD-450103A21BEF"><gtr:id>8D05D9D6-BFC5-46B7-B0CD-450103A21BEF</gtr:id><gtr:title>The crystal structure of the human titin:obscurin complex reveals a conserved yet specific muscle M-band zipper module.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14b89fa1a299acfb1cb2e5eb468e7110"><gtr:id>14b89fa1a299acfb1cb2e5eb468e7110</gtr:id><gtr:otherNames>Pernigo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6B6B6B0D-8428-478B-91D2-6C7DB6769AD7"><gtr:id>6B6B6B0D-8428-478B-91D2-6C7DB6769AD7</gtr:id><gtr:title>Diggin' on u(biquitin): a novel method for the identification of physiological E3 ubiquitin ligase substrates.</gtr:title><gtr:parentPublicationTitle>Cell biochemistry and biophysics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88571a92bec56cee858f5cf2c60f7e9e"><gtr:id>88571a92bec56cee858f5cf2c60f7e9e</gtr:id><gtr:otherNames>Rubel CE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1085-9195</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0C94C668-5EEE-4719-A0BD-7B8F202715ED"><gtr:id>0C94C668-5EEE-4719-A0BD-7B8F202715ED</gtr:id><gtr:title>Recessive TTN truncating mutations define novel forms of core myopathy with heart disease.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d278d82b034d5730cab1b5d588400d77"><gtr:id>d278d82b034d5730cab1b5d588400d77</gtr:id><gtr:otherNames>Chauveau C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98EA17B5-E95B-4697-BA0E-36D232ED25C9"><gtr:id>98EA17B5-E95B-4697-BA0E-36D232ED25C9</gtr:id><gtr:title>Recessive mutations in EPG5 cause Vici syndrome, a multisystem disorder with defective autophagy.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1ae8a0563763e2e20d182af2460349e"><gtr:id>f1ae8a0563763e2e20d182af2460349e</gtr:id><gtr:otherNames>Cullup T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AD83E388-CCC7-46C5-90B3-697C05A86605"><gtr:id>AD83E388-CCC7-46C5-90B3-697C05A86605</gtr:id><gtr:title>Combination of Whole Genome Sequencing, Linkage, and Functional Studies Implicates a Missense Mutation in Titin as a Cause of Autosomal Dominant Cardiomyopathy With Features of Left Ventricular Noncompaction.</gtr:title><gtr:parentPublicationTitle>Circulation. Cardiovascular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0ea61ab0db82267d769c3c39420ff22"><gtr:id>e0ea61ab0db82267d769c3c39420ff22</gtr:id><gtr:otherNames>Hastings R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1942-3268</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A2AFF570-85E0-4BCB-84FC-D308088453CF"><gtr:id>A2AFF570-85E0-4BCB-84FC-D308088453CF</gtr:id><gtr:title>Developmental regulation of MURF E3 ubiquitin ligases in skeletal muscle.</gtr:title><gtr:parentPublicationTitle>Journal of muscle research and cell motility</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1fe8eb2bfe4b5a478a45911c122e1558"><gtr:id>1fe8eb2bfe4b5a478a45911c122e1558</gtr:id><gtr:otherNames>Perera S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0142-4319</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F605EEDB-B9AF-4F5A-9F7D-27EF1B81AB98"><gtr:id>F605EEDB-B9AF-4F5A-9F7D-27EF1B81AB98</gtr:id><gtr:title>Current and future therapeutic approaches to the congenital myopathies.</gtr:title><gtr:parentPublicationTitle>Seminars in cell &amp; developmental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8cfe3367645d225c21a352c13d7fb7e7"><gtr:id>8cfe3367645d225c21a352c13d7fb7e7</gtr:id><gtr:otherNames>Jungbluth H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1084-9521</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/294B4092-B7A2-4B6E-8875-E65B62E7C6FA"><gtr:id>294B4092-B7A2-4B6E-8875-E65B62E7C6FA</gtr:id><gtr:title>Clinical utility gene card for: Vici Syndrome.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f1ae8a0563763e2e20d182af2460349e"><gtr:id>f1ae8a0563763e2e20d182af2460349e</gtr:id><gtr:otherNames>Cullup T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1A4CCF2-DA01-4BED-81C8-29A6B52154A4"><gtr:id>E1A4CCF2-DA01-4BED-81C8-29A6B52154A4</gtr:id><gtr:title>Binding partners of the kinase domains in Drosophila obscurin and their effect on the structure of the flight muscle.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3ae428298ab9dfffebd7349bdc47a4aa"><gtr:id>3ae428298ab9dfffebd7349bdc47a4aa</gtr:id><gtr:otherNames>Katzemich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B6A3A4A-32B4-492A-B9B0-18EEE8DC3F7E"><gtr:id>9B6A3A4A-32B4-492A-B9B0-18EEE8DC3F7E</gtr:id><gtr:title>Phosphoregulation of the titin-cap protein telethonin in cardiac myocytes.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a2cc0f14157c7ea0c04fdf092f53a1c"><gtr:id>6a2cc0f14157c7ea0c04fdf092f53a1c</gtr:id><gtr:otherNames>Candasamy AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/624DCBDD-C18B-42E7-A7CB-97E51348D009"><gtr:id>624DCBDD-C18B-42E7-A7CB-97E51348D009</gtr:id><gtr:title>Binding of Myomesin to Obscurin-Like-1 at the Muscle M-Band Provides a Strategy for Isoform-Specific Mechanical Protection.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/14b89fa1a299acfb1cb2e5eb468e7110"><gtr:id>14b89fa1a299acfb1cb2e5eb468e7110</gtr:id><gtr:otherNames>Pernigo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B31AF3EC-D680-415E-B27A-4408CAE53932"><gtr:id>B31AF3EC-D680-415E-B27A-4408CAE53932</gtr:id><gtr:title>Epigenetic changes as a common trigger of muscle weakness in congenital myopathies.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f5c8082802ec778386ca3cc5c516bf7e"><gtr:id>f5c8082802ec778386ca3cc5c516bf7e</gtr:id><gtr:otherNames>Rokach O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B9AC0ECD-69A7-4EB7-BF0D-B2BE2279689F"><gtr:id>B9AC0ECD-69A7-4EB7-BF0D-B2BE2279689F</gtr:id><gtr:title>MuRF1 activity is present in cardiac mitochondria and regulates reactive oxygen species production in vivo.</gtr:title><gtr:parentPublicationTitle>Journal of bioenergetics and biomembranes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1be75e20e93dc71e4edeb20d46858d2b"><gtr:id>1be75e20e93dc71e4edeb20d46858d2b</gtr:id><gtr:otherNames>Mattox TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0145-479X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A5D1A0D-DC91-4CD0-9B23-2B3042F3964F"><gtr:id>0A5D1A0D-DC91-4CD0-9B23-2B3042F3964F</gtr:id><gtr:title>The sarcomeric cytoskeleton: from molecules to motion.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/39b061ea1d9e351b3b409b6c8ff05635"><gtr:id>39b061ea1d9e351b3b409b6c8ff05635</gtr:id><gtr:otherNames>Gautel M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-0949</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C93C408E-2537-41A0-8799-ABDDF68923C7"><gtr:id>C93C408E-2537-41A0-8799-ABDDF68923C7</gtr:id><gtr:title>Pathogenic mechanisms in centronuclear myopathies.</gtr:title><gtr:parentPublicationTitle>Frontiers in aging neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8cfe3367645d225c21a352c13d7fb7e7"><gtr:id>8cfe3367645d225c21a352c13d7fb7e7</gtr:id><gtr:otherNames>Jungbluth H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1663-4365</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D66A3BB6-8C03-4C72-B972-876E301EF86A"><gtr:id>D66A3BB6-8C03-4C72-B972-876E301EF86A</gtr:id><gtr:title>The structure and regulation of human muscle a-actinin.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3d81004f56ac58dc9576640ab50a5bbd"><gtr:id>3d81004f56ac58dc9576640ab50a5bbd</gtr:id><gtr:otherNames>Ribeiro Ede A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78E2BEA5-D65C-4F91-819C-FAE749F65361"><gtr:id>78E2BEA5-D65C-4F91-819C-FAE749F65361</gtr:id><gtr:title>Solution NMR assignment of the heavy chain complex of the human cardiac myosin regulatory light chain.</gtr:title><gtr:parentPublicationTitle>Biomolecular NMR assignments</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/63f86f8759582aed806112a80e2bd6c8"><gtr:id>63f86f8759582aed806112a80e2bd6c8</gtr:id><gtr:otherNames>Rostkova E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1874-270X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6540C9D0-2053-45D7-BBF8-9D19AD110A90"><gtr:id>6540C9D0-2053-45D7-BBF8-9D19AD110A90</gtr:id><gtr:title>The Cardiac Stress Response Factor Ms1 Can Bind to DNA and Has a Function in the Nucleus.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d67f8631f3149b7544754694e851da3"><gtr:id>4d67f8631f3149b7544754694e851da3</gtr:id><gtr:otherNames>Zaleska M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J010456/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>